Why Is Ocular Therapeutix Stock Gaining Monday?
Ocular Therapeutix Inc. (NASDAQ: OCUL) stock is trading higher on Monday after its rival, EyePoint Inc. (NASDAQ: EYPT), released underwhelming Phase 3 trial data for its wet AMD treatment. EyePoint's Duravyu failed to meet its primary visual acuity endpoint, which analysts believe validates Ocular Therapeutix's own wet AMD treatment, Axpaxli (OTX-TKI). William Blair analysts noted that despite differences in trial design, EyePoint's data supports Axpaxli's profile as a durable and effective treatment, reducing risk for Ocular Therapeutix's ongoing studies and potential FDA approval.
OCUL Stock Climbs As FDA Clears Path For AXPAXLI NDA
Ocular Therapeutix Inc. (OCUL) stock climbed by 8.12% after the FDA agreed that a single successful Phase 3 SOL-1 trial, combined with safety data, is sufficient for an AXPAXLI wet AMD New Drug Application (NDA) via the 505(b)(2) pathway. The company reported a Q2 2026 net loss of $0.35 per share and $13.5M in revenue, slightly beating consensus, and has a cash runway into 2028. This regulatory de-risking and promising post-hoc SOL-1 data, suggesting a significant reduction in injection burden for wet AMD patients, are key drivers for investor optimism and analyst reiterations of Outperform ratings.
EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate
EyePoint Pharmaceuticals (EYPT) shares plummeted after its wet AMD treatment, Duravyu, failed its primary endpoint in a Phase 3 trial, putting the stock on track for a 16-month low. In contrast, rival Ocular Therapeutix (OCUL) saw its shares surge as its SOL-1 Phase 3 trial for a similar condition met its primary endpoint, leading retail investors to consider OCUL a stronger buyout candidate. Despite the primary endpoint miss, Duravyu met several secondary goals, and EyePoint anticipates results from a second Phase 3 trial in Q4 2026.
Ocular Therapeutix stock rises as rival’s wet AMD trial stumbles
Ocular Therapeutix Inc (NASDAQ:OCUL) shares rose after its competitor EyePoint Pharmaceuticals (NASDAQ:EYPT) announced that its DURAVYU treatment failed to meet the primary endpoint in a Phase 3 wet AMD trial. EyePoint's trial showed that DURAVYU did not achieve the primary endpoint of visual acuity change versus aflibercept, although an ad hoc analysis excluding a small cohort of patients suggested non-inferiority. Both companies are developing extended-release treatments for retinal diseases like wet AMD, aiming to reduce the frequency of injections.
Ocular Therapeutix (OCUL) Posts Wider Losses And Files Shelf Registration, Is It Still Undervalued?
Ocular Therapeutix (OCUL) is under investor scrutiny after reporting wider losses and filing a shelf registration for potential future stock issuance, causing recent share price fluctuations. Despite being down year-to-date, the stock is considered significantly undervalued by some analysts, primarily due to the anticipated approval of AXPAXLI for wet AMD. However, the company's valuation remains heavily dependent on trial outcomes and future funding needs.
OCUL|Ocular Therapeutix Inc|Price:9.890|Chg%:-0.210
This article provides detailed financial and analytical data for Ocular Therapeutix Inc (OCUL), including its live stock price, chart, news, and a comprehensive stock score. It covers key financial figures, performance over various periods, technical analysis, analyst ratings, and company profile. The data shows OCUL currently trades at $10.040, with analysts giving it a "Buy" rating and a target price significantly higher than its current value.
Ocular Therapeutix (NASDAQ:OCUL) Raised to "Hold" at Zacks Research
Zacks Research upgraded Ocular Therapeutix (NASDAQ:OCUL) from a "strong sell" to a "hold" rating. Despite this change, the consensus among analysts remains a "Moderate Buy" with an average price target of $25.75, reflecting broad positive sentiment. The company recently reported better-than-expected quarterly results, with institutional investors increasing their stakes, although insiders have sold a small number of shares.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. announced inducement awards to Ms. Beth Rada, the new SVP, Government Affairs and Public Policy. These awards, consisting of stock options and restricted stock units, are material to her employment acceptance under Ocular’s 2019 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants vest over several years, contingent on her continued service to the company.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. announced inducement grants to Ms. Beth Rada, the new SVP of Government Affairs and Public Policy. These awards, consisting of stock options and restricted stock units, were granted under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4) to induce her employment. The grants vest over several years, contingent on her continued service to the company.
Ocular Therapeutix’s New Policy Leader Gets an 85,000-Share Option
Ocular Therapeutix (NASDAQ: OCUL) has granted its new SVP, Government Affairs and Public Policy, Beth Rada, inducement equity awards under its 2019 Inducement Stock Incentive Plan. These awards, effective August 10, 2026, include a non-statutory option to purchase up to 85,000 shares at $9.24 per share, vesting over four years, and 28,000 restricted stock units vesting in three equal annual installments. The grants are intended to incentivize Ms. Rada's employment and are in accordance with Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. announced inducement grants to Ms. Beth Rada, the new SVP, Government Affairs and Public Policy, effective August 10, 2026. These awards, consisting of stock options and restricted stock units, were made under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are part of Ms. Rada's employment inducement and are subject to vesting schedules and continued service to the company.
Ocular Therapeutix (OCUL) Posts Wider Losses And Files Shelf Registration, Is It Still Undervalued?
Ocular Therapeutix (OCUL) is under investor scrutiny following wider quarterly losses and a new shelf registration filing, which could lead to future stock dilution. Despite a recent share price rebound, the stock remains down year-to-date. The company's valuation is heavily tied to the potential approval of its wet AMD product, AXPAXLI, with varying fair value estimates from analysts and internal models.
Dimensional Fund Advisors LP Takes $5.49 Million Position in Ocular Therapeutix, Inc. $OCUL
Dimensional Fund Advisors LP has initiated a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL), purchasing 649,756 shares valued at approximately $5.49 million. This move is part of broader institutional interest, with hedge funds and other institutional investors collectively owning 59.21% of the biopharmaceutical company's stock. Analysts generally maintain a "Moderate Buy" rating for OCUL, with a consensus target price of $25.75, following the company's recent earnings beat.
Janus Henderson Group PLC Has $581,000 Holdings in Ocular Therapeutix, Inc. $OCUL
Janus Henderson Group PLC significantly reduced its stake in Ocular Therapeutix by 98.4% in the first quarter, now holding 68,500 shares valued at $581,000. Despite this, institutional investors collectively own 59.21% of the company. Ocular Therapeutix reported better-than-expected Q1 earnings, with a loss of $0.35 per share against an estimated $0.40, and revenue slightly above forecasts, though the company remains unprofitable.
Ocular Therapeutix, Inc. $OCUL Shares Acquired by The Manufacturers Life Insurance Company
The Manufacturers Life Insurance Company significantly increased its stake in Ocular Therapeutix (NASDAQ:OCUL) by 145.9% in the first quarter, now owning 227,808 shares. This acquisition is part of a broader trend of institutional investment, with hedge funds and institutional investors collectively owning 59.21% of the biopharmaceutical company's stock. Despite a recent insider stock sale, analysts maintain a "Moderate Buy" consensus rating for OCUL, with an average target price of $25.75 against its current $9.19 share price.
The debate of durability in nAMD
This article discusses the evolving focus in treating wet age-related macular degeneration (AMD) from efficacy to durability. It highlights the importance of reducing treatment burden for patients, caregivers, and physicians, while also emphasizing that "rescue-free rates" and "time-to-first-rescue" are more meaningful measures of durability than just reduced injection frequency. The authors argue that a comprehensive assessment of new therapies must consider all patient interventions and how sustained disease control is achieved without additional interventions.
Does Ocular Therapeutix (OCUL) Pairing Flat Revenue With a New Shelf Point to a Shifting Funding Strategy?
Ocular Therapeutix (OCUL) reported flat Q2 2026 revenue of US$13.48 million and a widened net loss of US$78.76 million. Coinciding with these results, the company filed an US$81.7 million shelf registration for up to 10 million shares, indicating a strategic move to maintain funding flexibility despite existing cash reserves. This development highlights the ongoing financing risk, particularly given the company's reliance on its single dominant asset, AXPAXLI, and the need for successful progress in its SOL-1 and SOL-R trials.
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda?
Ocular Therapeutix (OCUL) shares rose 5% ahead of its Investor Day, driven by the announcement of its regulatory strategy for Axpaxli, an experimental wet age-related macular degeneration (AMD) therapy. The company plans to submit its New Drug Application (NDA) in Q4 2026, supported by Phase 3 SOL-1 trial data and interim safety data from the SOL-R study. Ocular is also streamlining its diabetic retinopathy program to focus on a single Phase 3 study, HELIOS-3.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. announced inducement equity awards granted to eight new non-executive employees. These awards, consisting of stock options and restricted stock units, were issued under the company's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4) to attract and retain talent. The grants are part of the company's efforts to further its integrated biopharmaceutical goals, particularly with its investigational product candidates for retinal diseases.
Ocular Therapeutix (NASDAQ:OCUL) Upgraded to "Hold" at Wall Street Zen
Ocular Therapeutix (NASDAQ:OCUL) has been upgraded from a "sell" to a "hold" rating by Wall Street Zen. The company reported quarterly revenue of $13.47 million and an adjusted loss of $0.35 per share, exceeding analyst estimates. Despite the upgrade, other analysts maintain a "Moderate Buy" consensus with an average price target of $25.75 for the stock.
Ocular Therapeutix Options for New Hires Carry $8.40 Price
Ocular Therapeutix (NASDAQ: OCUL) has granted inducement equity awards to eight new non-executive employees, including stock options for up to 53,975 shares and restricted stock units for 17,450 shares, effective August 3, 2026. The stock options have an exercise price of $8.40 per share, matching the closing price on the grant date, and vest over four years, while RSUs vest in three equal annual installments, both contingent on continued service. These grants were made under the company's 2019 Inducement Stock Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
Here's What Analysts Are Forecasting For Ocular Therapeutix, Inc. (NASDAQ:OCUL) After Its Second-Quarter Results
Ocular Therapeutix Inc. (NASDAQ:OCUL) recently reported strong second-quarter results, with revenues beating expectations. Analysts have modestly increased their optimism regarding loss per share predictions for 2026, though revenue forecasts remain unchanged. The consensus price target for OCUL stock held steady at US$27.09, despite the improved loss estimates, and the company's revenue growth is expected to slow compared to both its historical performance and the wider industry.
Here's What Analysts Are Forecasting For Ocular Therapeutix, Inc. (NASDAQ:OCUL) After Its Second-Quarter Results
Ocular Therapeutix (NASDAQ:OCUL) recently released strong second-quarter results, beating revenue expectations and posting smaller-than-anticipated statutory losses. Analysts have slightly increased their optimism regarding per-share losses for 2026, though revenue forecasts remain unchanged. Despite this, the consensus price target of US$27.09 has not shifted, and the company's projected revenue growth is expected to be slower than the broader industry.
Here's What Analysts Are Forecasting For Ocular Therapeutix, Inc. (NASDAQ:OCUL) After Its Second-Quarter Results
Ocular Therapeutix, Inc. (NASDAQ:OCUL) recently reported strong second-quarter results, with revenues exceeding expectations. Analysts have maintained their revenue forecasts for 2026 at US$52.6m, while modestly increasing their optimism regarding loss per share, now predicted to be US$1.48. Despite these adjustments, the consensus price target remains unchanged at US$27.09, reflecting that the reduced loss estimates have not significantly altered the long-term valuation outlook.
Ocular Therapeutix reports Q2 2026: $13.5M revenue, $78.8M net loss, $598.6M cash
Ocular Therapeutix announced its second-quarter 2026 results, reporting $13.5 million in product revenue, a net loss of $78.8 million, and a strong cash position of $598.6 million. The company is advancing AXPAXLI for wet AMD, with an NDA submission planned for Q4 2026, supported by positive trial data and FDA alignment. They also provided updates on clinical programs for diabetic retinopathy and are preparing for a potential 2027 market launch for AXPAXLI, expecting a cash runway into 2028.
Ocular Therapeutix Reports Second Quarter Revenue, Provides Business Highlights
Ocular Therapeutix reported flat second-quarter 2026 revenue of $13.5 million compared to the previous year, alongside an increased net loss of $78.8 million. The company is advancing its investigational drug Axpaxli for wet AMD, with plans to submit an NDA in Q4 2026, and anticipates its current cash balance of $598.6 million will fund operations into 2028. R&D and selling/marketing expenses rose due to ongoing clinical trials and pre-commercialization efforts for Axpaxli.
Ocular Therapeutix (OCUL) Stock Faces Axpaxli Hopes Against Deepening Losses
Ocular Therapeutix (OCUL) saw a modest 3% stock increase after Q2 2026 earnings, which showed flat revenue and widened net losses, keeping the focus on long-term growth and its pipeline. The company's bullish case hinges on Axpaxli, its wet AMD therapy, showing strong clinical progress and a clear path to FDA approval by Q4 2026. However, concerns remain about cash burn and concentration risk as Axpaxli's development still requires significant investment before commercialization.
Ocular estimates AXPAXLI treatment burden up to 72% below projected aflibercept
Ocular Therapeutix reported its Q2 2026 financial results, including $13.5 million in net revenue and a net loss of $78.8 million. The company plans to submit a New Drug Application (NDA) for AXPAXLI for wet AMD in Q4 2026, leveraging the 505(b)(2) pathway to potentially accelerate FDA review. A post-hoc analysis of the SOL-1 trial indicated that AXPAXLI could reduce treatment burden by up to 72% compared to aflibercept.
Ocular Therapeutix Inc earnings beat by $0.03, revenue topped estimates
Ocular Therapeutix Inc (NASDAQ: OCUL) reported Q2 EPS of $-0.35, beating analyst estimates by $0.03, and revenue of $13.48M, surpassing the consensus of $13.2M. Despite the earnings beat, the company's stock price has declined by 15.86% in the last three months and 33.85% over the past year. InvestingPro notes Ocular Therapeutix Inc's financial health as "weak performance."
Ocular Therapeutix Inc earnings beat by $0.03, revenue topped estimates
Ocular Therapeutix Inc (NASDAQ: OCUL) reported second-quarter earnings per share of $-0.35, which was $0.03 better than the analyst estimate. The company's revenue for the quarter also exceeded consensus estimates, coming in at $13.48 million against an estimated $13.2 million. Despite the earnings beat, Ocular Therapeutix Inc's stock price has seen a decline of 15.86% in the last 3 months and 33.85% in the last 12 months.
Ocular Therapeutix Releases Q2 2026 Financial Results
Ocular Therapeutix, Inc. reported a net loss of $78.8 million in Q2 2026, though its per-share loss narrowed to -$0.35 from -$0.39 year-over-year. The biopharmaceutical company generated $13.5 million in revenue, a slight increase of 0.1% from Q2 2025, primarily from DEXTENZA product sales. Despite continued losses, Wall Street analysts maintain a positive outlook, with a consensus of 11 buy ratings.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates
Ocular Therapeutix (OCUL) reported a Q2 loss of $0.35 per share, surpassing the Zacks Consensus Estimate of a $0.4 loss and beating revenue estimates with $13.48 million. Despite this, the company's shares have fallen 32.7% year-to-date, and its current Zacks Rank of #5 (Strong Sell) suggests expected underperformance in the near future.
Earnings Flash (OCUL) Ocular Therapeutix, Inc. Reports Q2 Revenue $13.5M, vs. FactSet Est of $13.2M
Ocular Therapeutix, Inc. (OCUL) announced its Q2 revenue reached $13.5 million, surpassing FactSet's estimate of $13.2 million. This financial update indicates that the company's revenue performance exceeded analyst expectations for the second quarter. The company also reported a widening net loss and flat revenue in a related announcement.
Ocular Therapeutix (NASDAQ:OCUL) Beats Expectations in Strong Q2 CY2026
Ocular Therapeutix (NASDAQ:OCUL) reported Q2 CY2026 results, beating Wall Street's revenue expectations with $13.48 million, though sales were flat year-on-year. The company's GAAP loss of $0.35 per share was an 11.2% improvement over analyst estimates. Despite ongoing high expenses and a negative operating margin, the company's stock rose 1.2% post-earnings, with analysts forecasting future revenue growth.
What Ocular Therapeutix (OCUL)'s Flat Quarter and AXPAXLI Trial Progress Means For Shareholders
Ocular Therapeutix reported flat first-quarter revenue, missing analyst expectations, which caused a 13% stock drop. Despite this, the company highlighted encouraging advancements in its AXPAXLI phase 3 trial for wet age-related macular degeneration, reinforcing its long-term focus on retinal opportunities. The success of AXPAXLI is crucial for offsetting current cash burn and justifying ongoing investments, though investors should be aware of the concentration risk associated with a single lead asset.
Ocular Therapeutix Inc (OCUL) Financial Health: Profitability & Balance Sheet Analysis
Ocular Therapeutix Inc (OCUL) has a financial score of 6.34, placing it 140 out of 155 in the Pharmaceuticals industry, indicating robust financial status but low operating efficiency. The company reported a Q1 revenue of $10.79M, a 0.81% year-over-year increase, and net profit surged by 38.34% year-over-year. While some key financial data is awaiting disclosure, the report highlights areas of quality of earnings, operational efficiency, growth potential, and shareholder returns.
What Ocular Therapeutix (OCUL)'s Flat Quarter and AXPAXLI Trial Progress Means For Shareholders
Ocular Therapeutix (OCUL) reported flat first-quarter revenue and missed analyst expectations, leading to a 13% stock drop. Despite this, the company highlighted encouraging progress in its AXPAXLI phase 3 trial for wet age-related macular degeneration, reinforcing its long-term potential. The article emphasizes that the clinical advancement of AXPAXLI is crucial for offsetting current cash burn and justifying future investments, given the company's reliance on this single asset.
What Ocular Therapeutix (OCUL)'s Flat Quarter and AXPAXLI Trial Progress Means For Shareholders
Ocular Therapeutix reported flat first-quarter revenue and missed analyst expectations, leading to a 13% stock drop. However, the company's CEO highlighted encouraging advancements in the AXPAXLI phase 3 trial for wet age-related macular degeneration. The investment narrative largely hinges on AXPAXLI's regulatory path, with recent additional data reinforcing its durability and safety, amidst concerns about sustained losses and potential dilution.
Ocular Therapeutix Inc (OCUL) Cash Flow
This article provides a detailed historical cash flow statement for Ocular Therapeutix Inc (OCUL), covering annual and quarterly data from FY2013Q1 to FY2026Q1 across operating, investing, and financing activities. It also includes frequently asked questions defining key cash flow metrics and highlighting OCUL's recent performance in these areas. The financial data serves to evaluate the company's financial soundness and stability.
Ocular Therapeutix Inc (OCUL) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Ocular Therapeutix Inc (OCUL)'s dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts or stock splits for the company, and provides current stock market data.
Ocular Therapeutix Inc (OCUL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Ocular Therapeutix Inc (OCUL), detailing its market capitalization and recent stock performance. It notes that relevant data regarding business segments and profit contribution have not yet been disclosed by the company. The only available regional revenue data indicates $51.95 million from the United States.
Ocular Therapeutix Inc Revenue Breakdown – BX:0OT
Ocular Therapeutix Inc. (BX:0OT) generated 41.19 million CHF in revenue last year, primarily from its Bioresorbable Hydrogel-based Formulation Technology segment. This revenue marks a decrease from the previous year's 57.64 million CHF for the segment. The United States remains the largest contributor to the company's revenue.
(OCUL) Price Dynamics and Execution-Aware Positioning
This article analyzes Ocular Therapeutix Inc. (NASDAQ: OCUL) using AI models, indicating weak sentiment across all time horizons and suggesting a short bias. It details three trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis highlights an exceptional risk-reward setup targeting a 21.9% gain versus 0.2% risk and provides multi-timeframe signal analysis for support and resistance levels.
Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment
Ocular Therapeutix plans to submit a New Drug Application (NDA) for AXPAXLI in wet age-related macular degeneration in Q4, following alignment with the FDA on the filing package. The company believes it meets evidentiary standards for a single-trial approval pathway and anticipates a complete submission. A pre-NDA meeting in Q3 will address operational logistics for the submission.
(OCUL) Price Dynamics and Execution-Aware Positioning
This article from Stock Traders Daily provides a detailed AI-driven analysis of Ocular Therapeutix Inc. (NASDAQ: OCUL), highlighting strong near and mid-term sentiment potentially shifting to a weak long-term outlook. It outlines specific institutional trading strategies, including long, breakout, and short positions, complete with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis indicating support and resistance levels.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. announced inducement grants to eleven new non-executive employees, consisting of stock options and restricted stock units. These awards, totaling 34,700 shares for options and 11,375 for RSUs, were made under Ocular’s 2019 Inducement Stock Incentive Plan as an inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The grants vest over several years, subject to continued service.
Does Ocular Therapeutix (OCUL) Joining Russell Value Indexes Quietly Recast Its Long‑Term Investor Base?
Ocular Therapeutix (OCUL) was recently added to several Russell Value indexes, which could increase its visibility to institutional investors and improve trading volumes. While this inclusion may boost short-term liquidity, the company's long-term investment narrative remains dependent on the success of its AXPAXLI clinical trials and regulatory approvals for wet AMD therapy. Investors should be aware of key risks such as AXPAXLI dependence, cash burn, and potential shareholder dilution, despite optimistic revenue forecasts and a projected fair value of $26.00 by 2029.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. announced inducement awards granted to eleven new non-executive employees under its 2019 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards, effective July 6, 2026, include non-statutory stock options for 34,700 shares and restricted stock units for 11,375 shares, designed to incentivize new hires. The awards vest over several years, contingent on continued employment.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. announced inducement grants to eleven new non-executive employees under Nasdaq Listing Rule 5635(c)(4) as a material inducement for their employment. These awards, effective July 6, 2026, include stock options for 34,700 shares and restricted stock units for 11,375 shares, vesting over three to four years. The grants are part of the company's 2019 Inducement Stock Incentive Plan.
Ocular Therapeutix (OCUL) Joins Russell Value Indexes, Is The Stock Now Too Pricey?
Ocular Therapeutix (OCUL), recently added to Russell indexes, has seen a sharp rebound in its stock price, but remains down year-to-date. Despite being considered "undervalued" with a fair value of $26 based on the potential of its drug AXPAXLI, its current price-to-sales ratio is significantly higher than industry averages, raising questions about its valuation. The article advises investors to review the underlying assumptions and risks, including potential setbacks for AXPAXLI or further shareholder dilution.
